Corticosteroid treatment for post-COVID-19 persistent interstitial lung disease: a randomized clinical trial. | ClinicLens

This study aimed to evaluate the efficacy of prednisolone in the treatment of persistent interstitial lung disease following severe SARS-CoV-2 pneumonia. A single-center, randomized, double-blind, placebo-controlled clinical trial was conducted. All participants presented residua

Medical Literature · Updated 2026-08-07

← Back to articles

This standalone article is served from the ClinicLens content archive.

If the embedded page does not load in your browser, open it directly.